How race and ethnicity affect treatment outcomes in breast cancer patients using CDK4/6 inhibitors
Impact of race and ethnicity on outcomes in patients with hormone receptor-positive breast cancer treated with CDK4/6 inhibitors
This study is looking at how well a new breast cancer treatment works for African American women compared to European American women, focusing on factors like genetics and access to care, to help make treatments better for everyone.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Texas Southern University NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10932910 on NIH RePORTER |
What this research studies
This research investigates the differences in treatment outcomes for hormone receptor-positive breast cancer patients, particularly focusing on African American women compared to European American women. It aims to understand how genetic factors, medication adherence, and social determinants of health influence the effectiveness of CDK4/6 inhibitors, a newer treatment option. By analyzing data from various sources, including the Cancer Genomic Atlas, the study seeks to identify why certain populations may not benefit as much from these therapies. The findings could help tailor treatment approaches to improve outcomes for underrepresented groups.
Who could benefit from this research
Good fit: Ideal candidates for this research are African American women diagnosed with hormone receptor-positive breast cancer who are being treated with CDK4/6 inhibitors.
Not a fit: Patients with other subtypes of breast cancer or those not receiving CDK4/6 inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for African American women with breast cancer, enhancing their survival rates and quality of life.
How similar studies have performed: Previous studies have shown disparities in treatment outcomes among different racial and ethnic groups, indicating that this research addresses a critical and previously identified gap.
Where this research is happening
Houston, United States
- Texas Southern University — Houston, United States (Active)
Researchers
- Principal investigator: Hunter, Rodney — Texas Southern University
- Study coordinator: Hunter, Rodney
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.